Harnessing The Power Of Digital Therapeutics In Pediatrics
Sponsored By Akili 
The ongoing cognitive health crisis continues to be a clinical and economic burden in the United States. Millions of people do not receive adequate treatment for cognitive impairment. For example, research has shown that the inattention and focusing difficulty seen in people with ADHD contribute to its classification as a cognitive impairment, but a general lack of awareness of these issues leads some to see ADHD as purely behavioral. This misappropriation has a negative effect on over 16 million people who have been diagnosed with ADHD in the United States, including over 6 million children. Although traditional ADHD management combines medications and psychosocial services, in many cases these treatments alone do not sufficiently manage ADHD symptoms. There is a need for a novel approach to treating ADHD that can complement a multimodal treatment plan.
Everyone deserves to have access to new and innovative treatments that address gaps in the current treatment landscape. But where do PDTx fit within the ADHD treatment protocol? How do they elevate the standard of care in ADHD? This session will highlight the role of PDTx in the management of ADHD with a focus on gaps in the current standard of care and strategies to navigate the access landscape for PDTx.
Learning Objectives: Upon completion of this discussion, participants should be able to:
- Understand the cognitive health crisis that exists today and the promise of PDTx to provide a solution
- Discuss ADHD and the gaps within the current standard of care
- Discuss how the technology is advancing the treatment protocol of current PDTx to treat ADHD
- Understand how the data behind PTDx is being utilized to advance treatment
Copyright © 2022 Akili Interactive Labs, Inc. All rights reserved. Privacy Notice. US-00630 8/22
*Assorted biscotti will be available as a morning break during this session!